Publication Name	World Journal of Diabetes
Manuscript ID	102390
Country	United Kingdom

Received	2024-10-16 18:56
Peer-Review Started	2024-10-18 00:56
To Make the First Decision
Return for Revision	2025-01-08 06:29
Revised	2025-01-08 20:37
Second Decision	2025-01-16 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-01-16 02:54
Articles in Press	2025-01-16 02:54
Publication Fee Transferred
Edit the Manuscript by Language Editor	2025-01-19 17:52
Typeset the Manuscript	2025-02-08 01:50
Publish the Manuscript Online	2025-02-28 10:45

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach
Manuscript Source	Invited Manuscript
All Author List	Vanishri Ganakumar, Cornelius J Fernandez and Joseph M Pappachan
Funding Agency and Grant Number
Corresponding Author	Joseph M Pappachan, MD, Professor, Faculty of Science, Manchester Metropolitan University, Lower Ormond Street, Manchester M15 6BH, United Kingdom. drpappachan@yahoo.co.in
Key Words	Glucagon-like polypeptide-1 receptor agonists; Cotransporter-2 inhibitors; Cardiovascular disease; Type 2 diabetes mellitus; Cardiovascular outcome trials
Core Tip	Glucagon-like polypeptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are important antihyperglycemic medications with cardiovascular (CV) benefits in the form of CV superiority or neutrality, and positive effects on cardiometabolic risk factors. The divergent clinical benefits include significant reductions in hospitalization for heart failure (HF) with SGLT2i, and ischemic stroke and myocardial infarction (MI) with GLP1RA. Zhu et al, in a recent issue of the World Journal of Diabetes, suggest combination therapy with GLP1RA/SGLT2i vs monotherapy with either agent for additional improvement in CV death and recurrent MI, especially in the setting of prior MI or HF.
Publish Date	2025-02-28 10:45
Citation	<p>Ganakumar V, Fernandez CJ, Pappachan JM. Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach. <i>World J Diabetes</i> 2025; 16(4): 102390</p>
URL	https://www.wjgnet.com/1948-9358/full/v16/i4/102390.htm
DOI	https://dx.doi.org/10.4239/wjd.v16.i4.102390

Full Article (PDF)	WJD-16-102390-with-cover.pdf
Manuscript File	102390_Auto_Edited_013941.docx
Answering Reviewers	102390-answering-reviewers.pdf
Audio Core Tip	102390-audio.m4a
Conflict-of-Interest Disclosure Form	102390-conflict-of-interest-statement.pdf
Copyright License Agreement	102390-copyright-assignment.pdf
Peer-review Report	102390-peer-reviews.pdf
Scientific Misconduct Check	102390-scientific-misconduct-check.png
Scientific Editor Work List	102390-scientific-editor-work-list.pdf
CrossCheck Report	102390-crosscheck-report.png
CrossCheck Report	102390-crosscheck-report.pdf